Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03177239 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 6, 2017
Last Update Posted : February 16, 2022
|
Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | December 31, 2021 |
| Estimated Study Completion Date : | December 31, 2022 |